Filtered By:
Condition: Heart Failure
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 268 results found since Jan 2013.

Aortic infective endocarditis: Value of surgery. About 48 cases.
CONCLUSION: The prognosis of infective endocarditis of the aortic valve is severe due to the fast progression to heart failure. Early medical and surgical approach provides good results on morbidity and mortality in the short- and mid-terms. PMID: 25813653 [PubMed - as supplied by publisher]
Source: Annales de Cardiologie et d'Angeiologie - March 23, 2015 Category: Cardiology Authors: Tribak M, Konaté M, Elhassani A, Mahfoudi L, Jaabari I, Elkenassi F, Boutayeb A, Lachhab F, Filal J, Maghraoui A, Bensouda A, Marmade L, Moughil S Tags: Ann Cardiol Angeiol (Paris) Source Type: research

Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit
Conclusions Few patients who require anticoagulation receive it in accordance with the guidelines even in a tertiary cardiology unit. There are many impediments to the effective use of VKA for stroke prevention among patients with AF.
Source: Heart Asia - April 21, 2015 Category: Cardiology Authors: Kew, G. S., Tan, M., Lim, T. W. Tags: Original research Source Type: research

Do CHA2DS2VASc and HAS‐BLED scores influence ‘real‐world’ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre
ConclusionsAntithrombotic management in AF is well implemented in Polish conditions, but we show the lack of pattern concerning who is being treated with OAC and ASA when it comes to the risk of stroke and bleeding. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - September 30, 2015 Category: Drugs & Pharmacology Authors: Paulina Lopatowska, Anna Tomaszuk‐Kazberuk, Elzbieta Mlodawska, Hanna Bachorzewska‐Gajewska, Jolanta Malyszko, Slawomir Dobrzycki, Wlodzimierz J. Musial Tags: Original Report Source Type: research

Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score
Abstract Recent findings suggest that patients with non-valvular atrial fibrillation (AF), in addition to having a high risk for ischemic stroke, are also at risk for myocardial infarction (MI). The aim of the study was to combine factors predicting Major Adverse Cardiovascular Events (MACE) in AF patients, including fatal/nonfatal MI, cardiac revascularization, and cardiovascular death, into a simple risk score. Predictors of MACE were obtained from a prospective observational cohort study, including 1019 AF patients taking vitamin K antagonists from the Atherothrombosis Center, of Sapienza University of Rome. Th...
Source: Internal and Emergency Medicine - October 15, 2015 Category: Emergency Medicine Source Type: research

Management of Atrial Fibrillation
Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. Common conditions associated with an increased incidence include advanced age, hypertension, heart failure, and valvular heart disease. Patients with atrial fibrillation may complain of palpitations, fatigue, and decreased exercise tolerance or may be completely asymptomatic. Options for treating patients who experience atrial fibrillation include rate-controlling drugs such as digoxin, β-blockers, and calcium channel blockers or a rhythm-controlling strategy with agents such as sodium channel blo...
Source: Journal of Intensive Care Medicine - October 29, 2015 Category: Intensive Care Authors: Zamani, P., Verdino, R. J. Tags: Analytic Reviews Source Type: research

Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part I: the thromboembolic risk.
Authors: Abrignani MG, Colivicchi F Abstract Atrial fibrillation, whose prevalence is in constant increase, is associated to a noticeably greater thrombo-embolic risk. Various associated factors, such as older age, arterial hypertension, heart failure, previous cerebrovascular events (stroke and transient ischemic attacks), diabetes mellitus, female sex and vascular diseases determine a further increase of the risk of stroke in patients with atrial fibrillation. Robust evidence exists on the efficacy of traditional anticoagulant oral therapy in the prevention of thrombo-embolic risk in these patients, but fears and...
Source: Monaldi Archives for Chest Disease - December 21, 2015 Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research

Cardioversion in Non-Valvular Atrial Fibrillation.
CONCLUSION: The main risks of cardioversion-thrombo - embolism and clinically significant hemorrhage-occur in 1% of cases or less (in the first 30 days after treatment) if the procedure is carried out as recommended in therapeutic guidelines. Serious complications still occur, but they are rare. PMID: 26763380 [PubMed - in process]
Source: Deutsches Arzteblatt International - January 15, 2016 Category: Journals (General) Tags: Dtsch Arztebl Int Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Heart Failure Clinics - March 9, 2016 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Better than Aspirin for Your Heart
If you’ve been diagnosed with heart disease, the chances are you’ve been told to take low-dose aspirin every day as a preventative measure against heart attack and stroke. It’s most commonly prescribed for patients with congestive heart failure. This is the inability of your heart to pump as much blood as your body needs. And this is a big worry to me, because there is very little evidence that aspirin helps. In fact, regular use of aspirin — even baby aspirin — can do you more harm than good. Common Aspirin Beliefs The idea is that aspirin thins the blood, making it easier to pump.  It is also s...
Source: Al Sears, MD Natural Remedies - April 1, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Heart Health Source Type: news

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF‐TIMI 48
ConclusionThe relative efficacy and safety of HDER compared with well‐managed warfarin in AF patients with HF were similar to those without HF.
Source: European Journal of Heart Failure - May 31, 2016 Category: Cardiology Authors: Giulia Magnani, Robert P. Giugliano, Christian T. Ruff, Sabina A. Murphy, Francesco Nordio, Marco Metra, Tiziano Moccetti, Veselin Mitrovic, Minggao Shi, Michele Mercuri, Elliott M. Antman, Eugene Braunwald Tags: Original Article Source Type: research

Vitamin K and non-vitamin K antagonists oral anticoagulants for non-valvular atrial fibrillation in real-life.
CONCLUSION: Patients given rivaroxaban and apixaban in clinical practice have a higher thrombotic and hemorrhagic risk in comparison with patients given dabigatran or VKAs. A considerable proportion of patients receive reduced doses of NOACs. PMID: 27394924 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - July 5, 2016 Category: Internal Medicine Authors: Giustozzi M, Vedovati MC, Verdecchia P, Pierpaoli L, Verso M, Conti S, Cianella F, Marchesini E, Filippucci E, Agnelli G, Becattini C Tags: Eur J Intern Med Source Type: research

Improved persistence with non-vitamin K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
CONCLUSIONS: Persistence with NOAC drugs in patients with AF appears to be superior to warfarin. If continued long-term, this alone will be of clinical importance in the prevention of stroke and death. PMID: 27463735 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 29, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

Thymosin β4: Roles in Development, Repair, and Engineering of the Cardiovascular System.
Abstract The burden of cardiovascular disease is a growing worldwide issue that demands attention. While many clinical trials are ongoing to test therapies for treating the heart after myocardial infarction (MI) and heart failure, there are few options doctors able to currently give patients to repair the heart. This eventually leads to decreased ventricular contractility and increased systemic disease, including vascular disorders that could result in stroke. Small peptides such as thymosin β4 (Tβ4) are upregulated in the cardiovascular niche during fetal development and after injuries such as MI, providing inc...
Source: Vitamins and Hormones - July 29, 2016 Category: Endocrinology Authors: Marks ED, Kumar A Tags: Vitam Horm Source Type: research

Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges
Atrial fibrillation (AF) and heart failure (HF) often coexist, and patients with AF and HF have a higher risk of thromboembolic events and overall mortality compared with those with AF without HF. Additionally, the prevalence of AF increases with the severity of HF. The use of vitamin K antagonists is more unstable in patients with concomitant AF and HF, which is an independent risk factor for reduced time under therapeutic range. More recently, non-vitamin K antagonists oral anticoagulants (NOACs) have emerged as therapeutic alternatives for stroke prevention in patients with non-valvular AF, as they have been shown to be...
Source: European Heart Journal - August 23, 2016 Category: Cardiology Authors: Ferreira, J. P., Girerd, N., Alshalash, S., Konstam, M. A., Zannad, F. Tags: Clinical update Source Type: research

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
CONCLUSIONS: There is evidence from RCTs to suggest that neither oral anticoagulation with warfarin or platelet inhibition with aspirin is better for mortality in systolic heart failure with sinus rhythm (high quality of the evidence for all-cause mortality and moderate quality of the evidence for non-fatal cardiovascular events and major bleeding events). Treatment with warfarin was associated with a 20% reduction in non-fatal cardiovascular events but a twofold higher risk of major bleeding complications (high quality of the evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (lo...
Source: Cochrane Database of Systematic Reviews - September 14, 2016 Category: Journals (General) Authors: Shantsila E, Lip GY Tags: Cochrane Database Syst Rev Source Type: research